HK1031825A1 - Cd154 blockade therapy for therapeutic protein inhibitor syndrome. - Google Patents

Cd154 blockade therapy for therapeutic protein inhibitor syndrome.

Info

Publication number
HK1031825A1
HK1031825A1 HK01101074A HK01101074A HK1031825A1 HK 1031825 A1 HK1031825 A1 HK 1031825A1 HK 01101074 A HK01101074 A HK 01101074A HK 01101074 A HK01101074 A HK 01101074A HK 1031825 A1 HK1031825 A1 HK 1031825A1
Authority
HK
Hong Kong
Prior art keywords
protein inhibitor
therapeutic protein
blockade therapy
inhibitor syndrome
exogenous protein
Prior art date
Application number
HK01101074A
Other languages
English (en)
Inventor
Burt Adelman
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of HK1031825A1 publication Critical patent/HK1031825A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
HK01101074A 1997-06-20 2001-02-14 Cd154 blockade therapy for therapeutic protein inhibitor syndrome. HK1031825A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (fr) 1997-06-20 1998-06-19 Therapie par blocage des cellules cd154 contre le syndrome inhibiteur de proteines therapeutiques

Publications (1)

Publication Number Publication Date
HK1031825A1 true HK1031825A1 (en) 2001-06-29

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01101074A HK1031825A1 (en) 1997-06-20 2001-02-14 Cd154 blockade therapy for therapeutic protein inhibitor syndrome.

Country Status (25)

Country Link
US (1) US20020119151A1 (fr)
EP (1) EP1034001B1 (fr)
JP (1) JP2002504910A (fr)
KR (1) KR100567998B1 (fr)
CN (2) CN1651071A (fr)
AT (1) ATE272408T1 (fr)
AU (1) AU733062B2 (fr)
BG (1) BG64436B1 (fr)
BR (1) BR9810755A (fr)
CA (1) CA2294138A1 (fr)
CZ (1) CZ295805B6 (fr)
DE (1) DE69825473T2 (fr)
EA (1) EA002512B1 (fr)
EE (1) EE9900587A (fr)
ES (1) ES2226152T3 (fr)
HK (1) HK1031825A1 (fr)
HU (1) HUP0002048A3 (fr)
IL (1) IL133305A0 (fr)
IS (1) IS2097B (fr)
NO (1) NO996274L (fr)
NZ (1) NZ502051A (fr)
PT (1) PT1034001E (fr)
SK (1) SK285962B6 (fr)
TR (1) TR199903141T2 (fr)
WO (1) WO1998058672A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20011021A3 (cs) * 1998-09-21 2001-10-17 Genetics Institute, Inc. Způsoby tlumení imunitní odpovědi na terapeutické proteiny
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
CN1835976B (zh) * 2003-06-13 2012-06-13 比奥根艾迪克Ma公司 无糖基抗-cd154(cd40配体)抗体及其用途
AU2004253868B2 (en) * 2003-06-13 2011-06-16 Biogen Ma Inc. Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
PT1682178E (pt) 2003-11-04 2010-10-21 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros que expressam o antigénio cd40
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
WO2007124299A2 (fr) 2006-04-21 2007-11-01 Novartis Ag Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012158789A2 (fr) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Procédés et compositions permettant d'inhiber la neddylation des protéines
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
ATE356634T1 (de) * 1997-01-10 2007-04-15 Biogen Idec Inc Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln

Also Published As

Publication number Publication date
JP2002504910A (ja) 2002-02-12
BG104092A (en) 2000-10-31
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
SK285962B6 (sk) 2007-12-06
IS2097B (is) 2006-04-12
ES2226152T3 (es) 2005-03-16
NO996274L (no) 2000-02-18
AU8153698A (en) 1999-01-04
WO1998058672A1 (fr) 1998-12-30
US20020119151A1 (en) 2002-08-29
DE69825473D1 (de) 2004-09-09
NZ502051A (en) 2001-04-27
DE69825473T2 (de) 2005-08-04
CN1651071A (zh) 2005-08-10
HUP0002048A2 (hu) 2000-10-28
CN1261285A (zh) 2000-07-26
EA002512B1 (ru) 2002-06-27
BG64436B1 (en) 2005-02-28
IL133305A0 (en) 2001-04-30
KR100567998B1 (ko) 2006-04-07
EP1034001A1 (fr) 2000-09-13
AU733062B2 (en) 2001-05-03
CA2294138A1 (fr) 1998-12-30
PT1034001E (pt) 2004-12-31
KR20010013964A (ko) 2001-02-26
IS5274A (is) 1999-11-26
CZ295805B6 (cs) 2005-11-16
TR199903141T2 (xx) 2000-09-21
BR9810755A (pt) 2000-08-15
EA200000059A1 (ru) 2000-08-28
EP1034001B1 (fr) 2004-08-04
CZ458899A3 (cs) 2000-04-12
ATE272408T1 (de) 2004-08-15
SK180399A3 (en) 2000-06-12
NO996274D0 (no) 1999-12-17

Similar Documents

Publication Publication Date Title
HK1031825A1 (en) Cd154 blockade therapy for therapeutic protein inhibitor syndrome.
WO2001021259A3 (fr) Procedes et compositions de traitement des pathologies apparentees aux plaquettes
WO2001024816A3 (fr) Compositions et procedes d'inhibition de la caseomorphine et de la gluteomorphine
AU2002360592A1 (en) Inhibitors of hepatitis c virus
GR3035971T3 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents.
MY114347A (en) Synergistic therapeutic compositions and methods.
AU4396993A (en) Dipeptidyl peptidase-I, cloning it, and therapeutic agents containing inhibitors thereof
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
WO2000041508A3 (fr) Polytherapie contre le cancer s'effectuant par activation de molecules de co-stimulation exprimees par des cellules immunitaires et des cytokines
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
EP1185283A4 (fr) Nouvelle utilisation therapeuthique de la proteine modulatrice de l'inflammation virale pour bloquer le rejet d'une xenogreffe
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
WO2003099212A3 (fr) Compositions d'inhibiteurs d une proteine kinase activee par des agents mitogenes et utiles dans la therapie du lymphome
AU9294698A (en) Methods and compositions for enhanced wound healing
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
IL136225A0 (en) Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
WO2004017902A3 (fr) Ubiquitine et molecules liees a l'ubiquitine destinees au traitement et a la prevention d'une activation nuisible du systeme immunitaire
IL124870A0 (en) Nitric oxide (no) synthase inhibitor to treat or prevent type ii diabetes
WO2001074341A3 (fr) Compositions et procedes pour le traitement d'etats allergiques et inflammatoires avec toux
PL337580A1 (en) Cd154 blocking therapy for treating a therapeutic protein inhibitor syndrome
MX9704579A (es) Composicion farmaceutica que comprende mirtazapina y uno o mas inhibidores selectivos de reabsorcion de serotonina.

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME AND ADDRESS OF PROPRIETOR FROM BIOGEN IDEC MA, INC, 14 CAMBRIDGE CENTER, CAMBRIDGE, MASSACHUSETTS 02142, UNITED STATES/UNITED STATES OF AMERICA TO BIOGEN IDEC MA INC., 14 CAMBRIDGE CENTER, CAMBRIDGE, MA 02142, UNITED STATES/UNITED STATES OF AMERICA.

Effective date: 20060331

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090619